August 5, 2021 7:44am
As the cell and gene therapy sector continue to project LPS (loss-per-share) results
Earnings’ releases today: Brainstorm Cell Therapeutics (BCLI), Caladrius Biosciences (CLBS), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO) and Intellia Therapeutics (NTLA)
Pre-open indications: 3 BUYs: CRSP, EDIT, IONS; 2 SELLs: SAGE, ALNY; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
There is no breadline for fact and numbers-based share pricing intelligence!
Dow futures are UP +0.14% (+48 points), S&P futures are UP +0.18% (+8 points) and NASDAQ futures are UP +0.21% (+32 points)
Stock futures are fluctuating yet, up in early pre-market trading on Thursday,
European markets were cautiously higher,
Asia-Pacific markets stayed up and held on to their recent gains in their morning trading
Data Docket: another update on the U.S. employment situation with the Labor Department’s latest weekly update to initial jobless claims.
Henry’omics:
Will jobless claims data contribute to Thursday’s session drift before Friday’s “real” numbers?
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542
Net Income:
- CRISPR Therapeutics (CRSP);
- uniQure NV (QURE);
Net losses:
- Ultragenyx Pharmaceuticals (RARE);
- Verastem (VSTM)
- Alnylam Pharmaceuticals (ALNY);
- Sage Therapeutics (SAGE);
- Global Blood Therapeutics (GBT)
- MiMedx (MDXG)
- Ionis Pharmaceuticals (IONS);
- Editas Medicine (EDIT);
- Vericel (VCEL);
- Brainstorm Cell Therapeutics (BCLI) - today;
- Intellia Therapeutics (NTLA) - today;
- Fate Therapeutics (FATE) - today
Wednesday’s evening’s recap: “the cell and gene therapy sector peaks and dives as sentiment remains unsupported” … https://www.regmedinvestors.com/articles/12034
- The Nasdaq closed UP +19.24 points (+0.13%);
- The IBB closed up +1.62% and XBI closed down -0.02%
- Sector volume was LOW with 4 of the 12-upside having higher than the 3-month average volume with very LOW volume of 3 of 19-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down – 0.07 points or -0.39% at 17.97;
- Wednesday’s percentage (%) of the 12-upside were +0.20% (QURE) to +19.97% (GBT) while the 19-downside ranges from -0.26% (SAGE) to -5.30% (SLDB);
Q3/21:
August: 1 positive and 2 negative close
July: 6 positives, 1 holiday and 15 negative closes
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed flat again on Wednesday with 50 shares traded after Tuesday’s flat with 616 shares traded after Monday’s -$0.05 to $1.60 with 571 shares traded.
Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Morning Indications:
BUY:
CRISPR Therapeutics (CRSP) closed up +$3.19 to $124.61 after Tuesday’s $121.42 and Monday’s $122.34 with a positive +$2.38 or +1.91% pre-market indication.
Editas Medicine (EDIT) closed up +$3.94 to $46.05 after Tuesday’s $42.11 and Monday’s $41.54 and last Friday’s $41.86 with a positive +$1.38 or +3% pre-market indication.
Ionis Pharmaceuticals (IONS) closed flat at $37.81 after Tuesday’s $37.81, Monday’s $37.63 and last Friday’s $37.14 with a positive +$0.69 or +1.82% pre-market indication.
SELL:
Sage Therapeutics (SAGE) closed down -$0.11 to $41.65 after Tuesday’s $41.76, Monday’s $43.37 and Friday’s $43.73 with a negative -$0.65 or -1.65% aftermarket indication.
Alnylam Pharmaceuticals (ALNY) closed up +$4.63 to $183.44 after Tuesday’s $178.81, Monday’s $177.96 and Friday’s $178.94 with a negative -$0.44 or -0.24% aftermarket indication.
Earnings preview:
Intellia Therapeutics (NTLA) reports Thursday and is expected to deliver flat earnings compared to the year-ago quarter on lower revenues when it reports results for the quarter ended June 2021. EDIT is projected to report earnings of -$0.61 per share, which would represent no growth from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $12.03 million, down 26.03% from the year-ago period. NTLA's full-year Zacks Consensus Estimates are calling for earnings of -$2.56 per share and revenue of $36.32 million. These results would represent year-over-year changes of -6.67% and -37.37%.
The BOTTOM LINE: Earnings continued to guide sector sentiment … this week after thirteen (13) releases to date …
Q2 earnings potential LPS (loss-per-share) later this week:
- Cellectis SA (CLLS) on Friday, 8/6
Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
Risk is no doubt increasing as we head into the troublesome August and September months
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
